Fachbereich Veterinärmedizin



    Infections with multidrug-resistant bacteria: Has the post-antibiotic era arrived in companion animals? (2015)

    Wieler, Lothar H. (WE 7)
    Walther, Birgit (WE 7)
    Vincze, Szilvia (WE 7)
    Günther, Sebastian (WE 7)
    Lübke-Becker, Antina (WE 7)
    Zoonoses - Infections Affecting Humans and Animals — Sing, Andreas (Hrsg.)
    Dordrecht: Springer Netherlands, 2015 — S. 433–452
    ISBN: 978-94-017-9456-5
    DOI: 10.1007/978-94-017-9457-2_17
    Institut für Mikrobiologie und Tierseuchen

    Robert-von-Ostertag-Str. 7-13
    Gebäude 35
    14163 Berlin
    +49 30 838 51840 / 51843

    Abstract / Zusammenfassung

    The increasing prevalence of infectious diseases caused by drug- and multidrug-resistant pathogenic bacteria in companion animals (dogs, cats, horses), particularly in veterinary hospitals, is a worrisome development. Regarding companion animals, currently the four clinically most important groups of multidrug-resistant pathogenic bacteria are methicillin-resistant Staphylococcus (S.) aureus (MRSA), methicillin-resistant S. pseudintermedius (MRSP), Extended-ß-lactamase-producing (ESBL) Enterobacteriaceae and multidrug-resistant Acinetobacter (A.) baumannii. Infections caused by these bacteria are often associated with clinical settings and involve mostly wound, skin, ear or urinary tract infections. S. pseudintermedius is a typical cause of canine skin infections and until recently regarded as being host-specific. However, the epidemic spread of MRSP together with the changing socio-cultural interaction between companion animals and humans has already resulted in human cases of MRSP infections. Just the opposite development was observed with MRSA. Here, typical hospital-associated (HA) genotypes originating from humans spread into companion animals, now being a substantial cause of disease. In both cases, typical non-zoonotic bacteria turned into zoonotic agents. These findings are just the tip of the iceberg when it comes to the influence of antimicrobial drug usage and multidrug-resistance in speeding up microbial evolution. Concerted action is urgently needed to slow down these processes.